Evaluation of Fibrolytic Effect of Bauhinia purpurea L.

Abstract

Background: Mammary gland tissue (left half) revealed the presence of excess proliferation of fibrous tissue with disorganization of alveolar structures and the right half showed extensive fibrous tissue proliferation of mammary gland following intramammary inoculation of 2000 c.f.u. of Staphylococcus aureus. However, oral dosing of Bauhinia variegata L. bark powder at 6 gm/kg for 7 days and 3 gm/kg for another 7 days exhibited reduction of fibrous tissue in chronic mastitis. Objective: The fibrolytic effect of one week oral dosing of Bauhinia purpurea L. bark powder was studied in chronic mastitis with induced fibrosis as Bauhinia variegate L. is rarely available in plain land. Methods: Chronic mastitis with fibrosis was induced by intramammary inoculation of coagulase positive Staphylococcus aureus in group III and IV goats. Group I and III goats were injected with a single dose of ceftriaxone at 20 mg/kg intravenously, whereas group II and IV goats were orally administered Bauhinia purpurea L. bark powder at 6 g/kg for 7 days with a single dose of ceftriaxone at 20 mg/kg intravenously. Results: The t1/2β of ceftriaxone with Bauhinia purpurea L. stem bark powder in chronic mastitis increased significantly. Ceftizoxime was detected in plasma from 1 h to 48 h post dosing (pd) in group III and from 1 h to 96 h pd in group IV, respectively. Conclusion: Bark powder of Bauhinia purpurea L. at 6g/kg orally once daily increased the bioavailability of ceftriaxone and or ceftizoxime in milk due to its fibrolytic effect which was not reported earlier. Therefore, the Bauhinia purpurea L. bark powder having fibrolytic effect has the potential to reduce development of cancer.

Prevention strategy for antimicrobial resistance development in bacteria through milk and conservation of antibiotic sensitivity

“…were also isolated from raw milk, pasteurized milk and yogurt samples (Marjan et al, 2014). Administration of antibacterial drugs to dairy animals suffering from chronic mastitis may also lead to lower concentration of antibacterial drugs in milk due to fibrosis (Dash et al, 2019). There are over 264 million dairy cow worldwide, producing nearly 600 million tonnes of milk every year.…”